TherapeuticsMD (TXMD) Reports In-Line Q4 EPS, Revenues Beat; Offers FY20 Product Revenue Guidance

TherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $15.9 million versus the consensus estimate of $12.83 million.

• 4Q19 Total Net Product Revenue of $15.9 Million Exceeded the Company’s Financial Guidance
• Full-Year 2019 Total Net Product Revenue of $34.1 Million at the Top End of Financial Guidance
• Company Launched ANNOVERA, a Novel, Long-Lasting Contraceptive
• Company Expects Full-Year 2020 Net Product Revenue of $90 Million to $110 Million

“I am very pleased with our commercial team’s execution in 2019, which has put us in a strong position for 2020. We ended the year exceeding our fourth quarter net revenue guidance and achieved the top end of our full-year guidance,” said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD. “Our goal is to build on this momentum as we make additional investments in our products to generate a significant revenue inflection point in 2020.”

GUIDANCE:

TherapeuticsMD sees FY2020 revenue of $90-100 million, versus the consensus of $100.15 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• American Express (AXP) down despite beating Q1 estimates on top and bottom lines
• Benchmark on Take-Two's (TTWO) GTV 6 Release: 'we anticipate that the game will not be released within the fiscal year and expect it to launch in fiscal 2026 instead'
• Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance